Overview

Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter Trial

Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the incidence of rate control (defined as: HR <110 beats/min or conversion to sinus rhythm) at 2 hours after medication administration between oral immediate release diltiazem and intravenous continuous infusion diltiazem.
Phase:
Phase 4
Details
Lead Sponsor:
Virginia Commonwealth University
Treatments:
Diltiazem